Strata Critical Medical (SRTA) Q3 2026 Earnings Call Transcript

Strata Critical Medical reported Q3 2026 revenue of $74.1 million, up 50.3% year over year, while pro forma revenue grew 8.5%; adjusted EBITDA rose to $9.6 million from $4.2 million and free cash flow reached a record $8.6 million. Logistics revenue fell 3.5% year over year amid a 10% industry decline in average trip distances, and management said it had not yet seen the typical seasonal volume improvement in Q4. The company reiterated 2026 revenue guidance of $285 million–$295 million and adjusted EBITDA guidance of $33 million–$35 million, and authorized a $20 million share repurchase program. Management targets high-teens organic adjusted EBITDA growth and at least 30% total adjusted EBITDA growth in 2027, including acquisitions. ಸಾಧ

Analysis

The core debate is whether SRTA is becoming a higher-value clinical platform or simply using acquisitions to mask modest underlying growth. The 8.5% pro forma revenue growth is the cleaner read-through than headline growth; 2027’s 30%+ EBITDA ambition therefore depends meaningfully on acquisition execution, not just operating leverage. Mid-single-digit purchase multiples sound attractive, but verify acquired cash conversion and integration costs before crediting that value.

Mix is the key second-order effect: integrated recovery can raise clinical utilization and economics while reducing transport intensity. That may support consolidated margins even as shorter flights pressure logistics revenue and owned-aircraft economics. A further offset is lower OCS carriage as customers adopt NRP and other preservation approaches; device partners may benefit, but SRTA’s case is that it captures more of the service relationship. Allocation changes could eventually expand volumes and distances, though timing is uncertain and the near-term lung-distance reset shows policy can also reverse part of the tailwind.

Near term, soft October activity and flat logistics expectations leave little room for a seasonal rebound to rescue a miss. The Q3 cash-flow record is also not a clean run rate given unusually low aircraft maintenance capex. Over 1–3 months, watch Q4 logistics volumes, clinical gross-margin recovery, and whether buybacks compete with disciplined M&A. Over 6–18 months, the thesis needs organic clinical growth, NRP adoption, and acquired EBITDA converting to cash. The contrarian risk: investors may extrapolate adjusted EBITDA targets while underweighting acquisition dependence, SBC, and variable maintenance needs.

Key Decisions for Investors

• Prefer a staged, conditional long in SRTA rather than chasing the reported growth: add only if Q4 results show clinical growth persists and clinical gross margin stabilizes or improves; require a valuation check against the company’s organic growth and cash conversion before sizing.
• Treat the 2027 EBITDA target as a catalyst, not a base case. Track pro forma organic growth separately from acquired contribution, and verify acquisition purchase consideration, integration costs, and acquired free-cash-flow conversion in filings.
• Keep exposure modest into Q4: a sustained low-single-digit or worse decline in transplant volumes, further logistics weakness, or clinical margin deterioration would falsify the near-term operating-leverage thesis and warrant reducing or avoiding the position.
• Do not underwrite Q3 free cash flow as normalized. Monitor aircraft maintenance capex and SBC in Q4; if maintenance needs rise while buybacks and acquisitions continue, shareholder returns and balance-sheet flexibility may be lower than the headline cash position suggests.